For research use only. Not for therapeutic Use.
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer[1].
BAY 2965501 increases natural killer cell- and T-cell-mediated tumor cell killing, and enhances IL2-induced natural killer cell activation[2].
BAY-2965501 inhibits tumor growth inhibition in an F9 testicular teratoma model, and the combination of BAY-2965501 with immune checkpoint blockade results in additive or synergistic effects[3].
| Catalog Number | I041293 |
| CAS Number | 2732902-08-6 |
| Synonyms | (2R)-2-(N-[4-amino-5-(4-methoxybenzoyl)-1,3-thiazol-2-yl]-4-fluoroanilino)propanamide |
| Molecular Formula | C20H19FN4O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19FN4O3S/c1-11(19(23)27)25(14-7-5-13(21)6-8-14)20-24-18(22)17(29-20)16(26)12-3-9-15(28-2)10-4-12/h3-11H,22H2,1-2H3,(H2,23,27)/t11-/m1/s1 |
| InChIKey | HSBUVKDEUUJREZ-LLVKDONJSA-N |
| SMILES | CC(C(=O)N)N(C1=CC=C(C=C1)F)C2=NC(=C(S2)C(=O)C3=CC=C(C=C3)OC)N |
| Reference | [1]. Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83(7_Supplement): 2116-2116. [2]. Rienk Offringa, et al. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Regular and Young Investigator Award Abstracts. Immune Cell Types and Biology. [3]. Schlicher L, et al. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status. Front Immunol. 2023 Oct 31;14:1297175. |
